Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Solid Tumors

  • Home
  • Solid Tumors
Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors
Posted inHematology-Oncology news Oncology

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

Posted by MedXY By MedXY 05/09/2026
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast cancer.
Read More
Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy
Posted innews Oncology Specialties

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy

Posted by MedXY By MedXY 09/15/2025
A phase Ib study evaluated the safety, optimal dosing, pharmacokinetics, and preliminary efficacy of metformin with nivolumab in refractory solid tumors, showing good tolerability and promising responses in a subset of patients.
Read More
  • Food Coloring Additives Linked to Higher Type 2 Diabetes Risk in a Large French Cohort
  • Precardioversion Heart Rhythm Monitoring Using Smartphone Photoplethysmography: The SMARTBEATS Randomized Clinical Trial
  • Long-Term Wildfire Smoke PM2.5 Exposure Is Linked to Higher Incident Stroke Risk in Older US Adults
  • Disrupted MAML1 Phase Separation Emerges as a New Mechanism Linking Notch Failure to Congenital Heart Disease
  • Language Barriers and Treatment Delays Emerge as Modifiable Threats in Early-Onset Colorectal Cancer
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in